The Chief Executive of US pharmaceutical company Eli Lilly says it will be hard to come back from this moment.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

The Chief Executive of Eli Lilly has told the BBC that he is doubtful tariffs could bring manufacturing jobs to the US whilst ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

We recently published a list of Jim Cramer’s Take on These 10 Stocks. In this article, we are going to take a look at where ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Killeen ISD has reported that Dr. Frederick Lilly submitted a resignation letter as the principal of Roy J. Smith Middle ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...